CD274 and non-small cell lung carcinoma: Meanwhile, the advent of immunotherapy leads to greater availability of effective subsequent treatments and extended survival in previously treated advanced non-small cell lung cancer (NSCLC), of which a good example is the success of clinical trials for PD-1/PD-L1 inhibitor in tumour treatment [4, 5].